Ā鶹ֱ²„
Ā鶹ֱ²„ & Lardner LLP of counsel William Holtz was quoted in The Wall Street Journalās article, ā,ā examining the risks and regulatory challenges facing compounding pharmacies supplying peptides.
Holtz noted that compounding pharmacies are manufacturing previously restricted peptides āwithout explicit permission from FDA.ā
He described the current regulatory landscape as a ādelicate balance the federal government is trying to strike: navigating a regulatory process meant to keep consumers safe against the possibility that these experimental drugs could help people with certain conditions.ā
(Subscription requried)
